Strengthening basic research

「The company focuses on R&D in the areas of myopia, dry eye, presbyopia and neurological diseases. R&D expenses for the fiscal year were ¥279.512 million.」

「In R&D, the company focused on basic research aimed at creating new intellectual property and expanding its pipeline, while continuously strengthening and promoting its joint R&D framework with domestic and overseas partners.」

「In R&D, we continued expanding collaboration with joint research institutions in basic research to discover new intellectual property and add new pipeline products. In addition to obtaining efficacy results in the preliminary findings from the specified clinical study of TLG-005 for depression and Parkinson’s disease, we expanded the indications for a glaucoma eye drop and completed subject enrollment in the specified clinical study of project TLM-007, which is being developed as an eye drop to prevent the progression of myopia. We also published a research paper entitled “Establishment of an in vitro choroidal complex for vascular response screening.”」

「The Company is focusing on R&D related to myopia, dry eye, presbyopia, and brain diseases, and R&D expenses for the current fiscal year amounted to ¥205.296 million.」

「In R&D, the Company continued basic research aimed at discovering new intellectual property and adding new pipelines, strengthening intellectual property out-licensing and R&D with partner companies conducting joint research, and conducting business activities with a view to entering the high-potential Chinese market. It also focused on commodity development in the healthcare field. Public funding was awarded to a research and development project aimed at preventing and enabling early intervention for cognitive decline in elderly dogs under the Small and Medium Enterprise Agency’s FY2023 Call for Proposals for the Research and Development Support Program for Growth-Oriented SMEs (Go-Tech Program). “Eye drops for treating scleral thinning and a screening method for scleral-thinning treatments” was also selected for funding under the FY2023 Subsidy Program for Foreign Patent Filing Expenses. The Company published research papers including “Violet light enhances EGR-1 expression via OPN5 in the mouse retina,” “Establishment of a mouse model of ER stress-induced myopia,” and “Instillation of bunazosin hydrochloride suppresses myopia progression by increasing choroidal blood flow.” Total R&D expenses for the cumulative period through the third quarter amounted to ¥143.105 million.」

「In R&D, the Company continued to strengthen basic research aimed at discovering new intellectual property and adding new pipelines, out-licensing intellectual property, and R&D with partner companies conducting joint research. Its research publications included “Identification of potential therapeutic targets for myopic choroidal neovascularization through data mining based on Discovery-Driven Planning” and “Effects of bisphenol A exposure on axial elongation and mechanisms affecting the sclera from the perspective of endoplasmic reticulum (ER) stress.”」

「In R&D, the Company continued to strengthen basic research aimed at discovering new intellectual property and adding new pipelines, out-licensing intellectual property, and R&D with partner companies conducting joint research. In April, it presented 10 research results at ARVO (The Association for Research in Vision and Ophthalmology), a globally authoritative organization in ophthalmic research. In June, it exhibited at the 2023 BIO International Convention, the world’s largest business-matching event, held in Boston, Massachusetts, presenting its proprietary knowledge, technologies, and product portfolio to the global market.」

「The Company is focusing on R&D related to myopia, dry eye, and presbyopia, and R&D expenses for the current fiscal year amounted to ¥126.266 million.」

「In R&D, the Company continued to strengthen basic research aimed at discovering new intellectual property and adding new pipelines, out-licensing intellectual property, and R&D with partner companies conducting joint research. It also continued the confirmatory clinical trial for TLG-001, a medical device for suppressing myopia using violet-light technology. A research group led by the Company’s representative, Kazuo Tsubota (坪田 一男), discovered new findings concerning the suppression of myopia progression, and the results were published online in the interdisciplinary journal Nature Communications. The Company also published papers on the results of an exploratory clinical trial using violet-light-emitting glasses and autonomic nervous system activity in dry eye accompanied by reduced tear-film stability.」

「In R&D, the Company continued to strengthen basic research aimed at discovering new intellectual property and adding new pipelines, out-licensing intellectual property, and R&D with partner companies conducting joint research. It also continued the confirmatory clinical trial for TLG-001, a medical device for suppressing myopia using violet-light technology, and announced research results including the discovery that dogs shed emotional tears through the action of the “love hormone” oxytocin and the discovery of a new function of vascular endothelial growth factor involved in suppressing the progression of myopia.」

「In R&D, the Company continued basic research aimed at discovering new intellectual property and adding new pipelines, out-licensing intellectual property, and strengthening R&D with partner companies conducting joint research.」

「The Company is currently at the basic research stage, which forms the foundation for royalty income, and will continue strengthening its basic research in order to conduct joint research and development with partner companies that evaluate its research results.」